0:01
It's November 20, 2026, and this is the RheumNow podcast.
0:06
Hi, I'm Dr. Jack Cush, executive editor of RheumNow.com.
0:10
In this session, we're going to do something a little bit different.
0:16
I'm going to pontificate on a subject I've been thinking about for a while.
0:22
Being an RA guy, an RA maven, I'd like to think that I can answer the question: how should I treat rheumatoid arthritis? What's the best way to treat it?
0:35
I get asked that all the time. I did a video on my approach to RA.
0:40
You could find it on YouTube, probably in 2025 would be my guess, maybe late 2024.
0:48
But this is going to be a departure. This is going to be a lecture about what is the best first drug to use in RA.
1:01
And the truth is that we really don't know, because the answer would lie in well-designed clinical trials for which there are none.
1:10
There are no RCTs that have answered the question: what is the best first drug in RA?
1:18
So we extrapolate from that. Our current guidelines are based on a lot of clinical trials that start patients at all stages of disease, but it doesn't say what you should use first.
1:33
So can you extrapolate from investigator-initiated trials or meta-analyses?
1:39
I don't know. I think the best way to look at this is to look at methotrexate-naive, early, DMARD-naive patients.
1:52
And in those studies, you know, you're going to start people on methotrexate with or without other therapies, or against other therapies, such as has been done in the NORDSTAR study, the BEST study, and TIER studies.
2:07
But again, those are pretty uni-dimensional in what they have done.
2:13
Network meta-analyses — there were two of them out there that showed that when methotrexate is started with a first-line biologic or JAK inhibitor, it does better than methotrexate monotherapy.
2:24
But again, these are network meta-analyses and not well-designed trials to really answer the question.
2:31
So you see someone, they need to be put on therapy for the first time.
2:34
Presumably, hopefully, they're early, and you've got to choose between what the guidelines say — methotrexate — what the guidelines may endorse — methotrexate plus glucocorticoids with bridging, or triple therapy, or methotrexate with a biologic.
2:51
That seems a little extreme. Or even crazier would be methotrexate with a JAK inhibitor, or, God forbid, a JAK inhibitor all by itself.
3:01
All of these options are supported by guidelines that to one extent or another are all done under the idea that you would be doing treat-to-target.
3:13
Let me tell you about a patient from 2003.
3:18
We had very few biologics on the market — just really three TNF inhibitors.
3:24
A 40-ish year old businessman, 38 maybe, married, just had a few kids, changed jobs, just got hired for what he thought was his executive dream job.
3:38
And in between his hire date and his start date, he develops new severe polyarticular rheumatoid arthritis.
3:48
I'm talking about like 12 or 14 swollen joints, hard to function.
3:53
He's panicked, comes to me and says he can't lose this job and he's starting in four weeks.
3:59
You know, if I went according to the guidelines, what would I have done?
4:04
I'd have delayed his onset and he'd have lost his job and his mind and probably his marriage.
4:10
That wasn't going to work. So yes, I did start him on methotrexate, folate, prednisone in a moderate dose trying to wean down over the next four weeks.
4:19
And then I had to give him something that was going to work fast and quick besides prednisone.
4:22
What was my best drug, my strongest drug at the time?
4:27
It was high-dose infliximab. And that's what he got.
4:29
He got an infusion at week zero, week two, and not week six, but at week four.
4:34
And you know what? At week four when he went to work, he was 75% better.
4:39
He kept his job. He got into remission. And we backtracked on therapy.
4:46
I didn't continue the rituximab because it was hard to even get it approved.
4:51
I'm going to spare you the stories where delays in diagnosis are nothing but horrors and horrible outcomes, especially for the patient, for the joint, for the X-rays.
5:04
I'm going to spare you the data on constipated serial use of DMARDs and whether they may or may not work.
5:12
Yeah, you know what the good news is? We do well most of the time, but not all the time.
5:18
So I think we need to rethink the paradigm and answer the question: what is your best first drug?
5:23
I know not all patients are the same. And you want to say, well, it depends.
5:29
I don't really like "it depends." I don't wear Depends.
5:32
I don't count on the word "depends." I like rules.
5:37
Rules that I can break, but rules that I've got to live by, come hell or high water.
5:42
The fact is that we often start slow, escalate slow, or are slow to change.
5:52
You know, that doesn't work. So a long time ago in the 80s, the great Fred Wolfe from Wichita, Kansas, said to me, "Why don't you use your best drug first?"
6:01
And he wrote an editorial about this in J Rheum.
6:03
And I would ask you: what is your best drug?
6:06
What you need to know is that the first choice you make is maybe the most important, because if you take methotrexate, only 30% are going to respond with either an LDA or remission-kind of response.
6:19
And thereafter, the people that don't respond — they're going to respond less well to your next choice, and less well to your third choice.
6:26
There is this decremental gain, if you will, in non-responsiveness with the more changes you make, and that's been proven by many, many studies.
6:41
So how are you going to choose what is your best drug?
6:44
You've got a lot to choose from. You have 10 biologics, 22 biosimilars, three FDA-approved JAK inhibitors in the United States, four worldwide, and seven FDA-approved DMARDs — methotrexate, hydroxychloroquine, gold, sulfasalazine, cyclosporine, and azathioprine. All FDA approved.
7:06
So maybe there are some new developments, new therapies that have come out that I should be thinking about or using because it's the next great thing.
7:14
I asked AI. I did four different AI searches and it seems to change month to month.
7:20
AI kind of likes to make new things up. The best AI could come up with is the EULAR 2025 guidelines — that's pretty good, but they're very conservative.
7:35
EULAR likes to point out, in no particular order: maybe you should use biosimilars — there are 22, 19 were FDA approved in 2024 alone.
7:47
EULAR likes to point out a bunch of nonsense that has no applicability to the question at hand.
7:52
CAR-T cell therapy for RA — there's one uncontrolled pilot study of six patients called the COMPETE trial.
7:58
The AI suggested vagal nerve stimulation — nope.
8:02
That's kind of for people that have failed therapy; they'd like you to use it first line, but it's not getting first line with me.
8:10
They talked about prevention strategies — I'm talking about people who actually have RA.
8:16
So ARIAA, AIPrA, ALTO studies don't apply.
8:19
They talk about precision medicine, biomarker use, anti-fibrotics, new targets, PD-1, Rozanolixizumab, BTK inhibitors, FcRn — these don't belong in your brand-new first drug choices.
8:35
Well, I gave up on AI. I looked at RheumNow.
8:38
What has RheumNow said in the last few years?
8:41
There's been no new drug development in RA for quite some time.
8:44
So yeah, RheumNow covered the 2025 EULAR recommendations, which are good, but I don't think they answer the question here.
8:52
They want you to use methotrexate first with or without steroids.
8:56
We wrote about hydroxychloroquine being important in RA patients — lowers hospitalizations, has secondary benefits.
9:05
We talked about being aggressive with treat-to-target in pregnancy — the PRECA versus PARADA studies — where they have better outcomes if they're treated to target with even aggressive therapies.
9:16
We talked about multimorbidity. We talked about methotrexate intolerance.
9:20
We talked about profiling difficult-to-treat RA patients by calling them a PIP — either NIRAs or PIAs: non-inflammatory refractory RA, which is really fibromyalgia, or PIAs, persistent inflammatory refractory RA, who need more aggressive anti-inflammatory, immunomodulatory therapy.
9:39
But maybe the most important thing we talked about in rheumatoid arthritis in the last three years is the hazards of depression.
9:45
The DANBIO study showed that if you had RA and you were depressed, you had a five- to eightfold higher risk of mortality.
9:57
But that still doesn't get me to the question, right?
10:01
So there are head-to-head trials, but they don't answer the question that we're talking about here.
10:08
I'd like to see more head-to-head trials.
10:10
I want to go with what Fred Wolfe said: use your best drug first.
10:15
And this is really about a few factors. One — is there a window of opportunity?
10:21
Window of opportunity means that the appropriate best intervention changes the long-term outcome, and that there's a window in which you get your best responses with your best drug.
10:36
It is a predictor for what will ensue thereafter.
10:38
Use your best drug first. That will change the trajectory of the patient's disease.
10:44
If you can flatten that trajectory as aggressively as possible early on — first 6 weeks, first six days, first 6 months — then the patient will probably do better.
10:56
The problem is that right now it's all guidelines and strategy.
11:01
The main thing in guidelines and strategy is: get the patient early, treat them aggressively, get the patient early, start them on methotrexate, get the patient early, do treat-to-target.
11:14
But no one gets early RA — really, not enough.
11:16
Nobody does treat-to-target; they think they do, but they don't.
11:22
And remission induction strategies have never been tested.
11:26
So without head-to-head trials, it still is: use the best data first.
11:30
So if you look at any algorithm on treatment of RA, it's very classic, very traditional — depending on how active they are, you choose methotrexate, go with milder therapy, and then if they don't do well, you switch and add on, maybe combination drugs, and then maybe biologics down the road.
11:49
But to get from your very first choice to your very first biologic is generally somewhere in the range of 2 to 5 years — the game is over.
12:00
The damage — the train has left the station.
12:03
The fibroblasts are running amok causing erosions that can't be turned off.
12:07
Why not use your best drug first? In my mind, that's JAK inhibitors.
12:13
What is he talking about? JAK inhibitors have been around since 2012.
12:21
Tofacitinib was FDA approved, and after that it was baricitinib, and then after that we've got upadacitinib in the rest of the world, and then — you know, we've done well.
12:36
What have we learned about JAK inhibitors since 2012?
12:38
Well, they're newer. They're more expensive.
12:40
They work faster — 2 to 6 weeks. They have less nuisance side effects.
12:45
Their serious adverse events are few and certainly not any more than what we get with any of the biologics — abatacept, IL-6 inhibitors, TNF inhibitors, you name it.
12:57
JAK inhibitors maybe have one distinctive serious adverse event, and that is herpes zoster, for which you can strategize and prevent.
13:04
They have many, many, many, many indications outside of rheumatology and inside rheumatology.
13:11
And then in 2020 — and then officially in 2021 — the ORAL Surveillance study ends up becoming a box warning on all the JAK
13:21
inhibitors, where you have to use a TNF before a JAK, and you have to worry about serious infections, but mainly cardiovascular and malignancy risks,
13:31
especially in high-risk individuals.
13:34
The studies were done in patients over 50 who had cardiovascular risk factors.
13:38
But really the high-risk individuals are people over 65 who have cardiac disease and who may or may not smoke.
13:47
That narrows the people you really have to worry about.
13:51
And the other major advance that's changing my story is that now in 2026, generic tofacitinib can be had for $5 for 5 milligrams twice daily — $25 a month for 11 mg XR, that's generic too — $33 a month.
14:11
Why would you use a JAK inhibitor, other than what my exclamation points were two seconds ago? Well, the generic. Yes.
14:20
Methotrexate remission rates have historically been said to be around 30%.
14:26
That's really LDA — low disease activity — and remissions in RCTs of DMARD-naive, methotrexate-naive individuals.
14:34
JAKs beat methotrexate every time. Methotrexate performance in three different JAK inhibitor trials — looking at about a 12 to 24 week endpoint — ACR remission rates: 8 to 19%.
14:54
The JAK inhibitors: 22 to 48%. And it looks even better than that in other trials.
14:59
JAKs always kick methotrexate in the buttocks.
15:04
Which is safer? JAKs are safer than methotrexate in my opinion — much safer.
15:11
Abatacept might be safer than JAKs. I think JAKs are probably safer than other biologics.
15:17
Hydroxychloroquine may be safer than all of them, but that's adjunctive therapy, not disease-modifying monotherapy that you use alone.
15:26
So again, the faster onset of action — and what are you hoping for your patients in head-to-head trials?
15:31
JAKs beat methotrexate: ORAL START study with tofacitinib, baricitinib versus methotrexate in 2017, upadacitinib versus methotrexate in 2019.
15:42
JAKs are better in three different trials against adalimumab: SELECT-COMPARE, RA-BEAM, and ORAL Strategy.
15:49
JAKs are better than abatacept. Now this is in established RA and it's like a third or fourth choice — many of them have failed TNFs — but JAKs were better than abatacept on efficacy, while ABBA was safer than JAKs.
16:04
So can that factor into your decisions? Obviously a lot of this is colored by the ORAL Surveillance study — over 4,000 patients, over four years of observation — basically ending up with a higher rate of cardiovascular events and certain malignancies in high-risk patients over the age of 50.
16:29
And that ended up becoming a box warning.
16:32
But you know, it really only applies — if you look at the data, as we've talked about here — it applies to over-65 smokers with a history of MI or CV events.
16:44
Which means that if you're not that patient, I wouldn't pay attention to the package insert guidelines.
16:54
I didn't have to. Remember, those package inserts are recommendations.
16:57
You're allowed to prescribe whatever you want.
17:01
You want to give naltrexone for itchy teeth and screwy eyeballs, go right ahead.
17:07
Now, if it doesn't work out, you may not win in court.
17:09
But this week, I saw a brand-new at-risk RA patient I've been following for two months who converted to early RA, and I put the patient on a JAK inhibitor.
17:22
Cost her $33 a month for 11 mg XR tofacitinib. She's going to be happy in a few weeks.
17:31
Now, can I defend this? Again, working against us is the ORAL Surveillance study.
17:39
Other data presented at EULAR is the RA-BRIDGE study, done with baricitinib — a post-regulatory commitment to study baricitinib in patients at high risk for VTE: patients who had a prior VTE, over the age of 60, obese or overweight with a BMI greater than 25.
17:59
That study did show that baricitinib versus TNF inhibitors had a higher rate of venous thromboembolic events, but did not have a higher risk of cardiovascular events or malignancy, and did have slightly more serious infection.
18:19
So it kind of reinforces ORAL Surveillance, but not fully.
18:25
There are, other than the many clinical trials done by the many companies, other studies that look at what happens when you give patients methotrexate or more aggressive therapy — either biologic or targeted synthetic.
18:41
A meta-analysis of 29 RCTs, almost 13,000 patients, shows a 62% chance of doing better with the more aggressive therapy at 12 months. Again, I think that's important.
18:52
There's a recent study that was in Mayo Clinic Proceedings in 2026 by Zhao et al — 116 DMARD-naive patients got either tofacitinib or methotrexate after a steroid injection.
19:05
At 3 months, tofacitinib was better at SDAI, CDAI, and CRP levels.
19:10
Safety was the same. Tofacitinib was more cost-effective in China, where it's much cheaper.
19:18
Again, JAK inhibitors have been available at a much lower price in Southeast Asia and in India for a long time.
19:26
So yes, methotrexate is the first line, but methotrexate's got more nuisance side effects.
19:34
JAK inhibitors may have more zoster events than TNF inhibitors or other DMARDs — 5 to 10-fold higher — so you vaccinate people going on a JAK.
19:44
JAK inhibitors are contraindicated in elderly smokers with a cardiovascular history, patients with a prior venous thromboembolic event, patients with intolerance to JAK inhibitors, and patients in whom you worry about hepatic toxicity.
19:58
GI perforation — I'm not sure that's a contraindication to me.
20:02
Again, the main driver of this decision is that it's now generic.
20:05
If you go to GoodRx and go to Walgreens or Duane Reade or a pharmacy in the United States, it's about $140 for the 5 mg twice-daily dose of tofacitinib.
20:17
But if you go to Mark Cuban's Cost Plus, it's $25 for 5 mg twice daily, a 30-day supply — they make you actually buy two months at a time.
20:27
If you look for the Xeljanz XR version, the tofacitinib extended release, it's $8 more — it's $33.
20:37
Again, that's what I prescribed this week.
20:41
So again, JAK inhibitors should be first line — use your best drug first, in my mind — because it beats methotrexate, it beats adalimumab
20:52
in methotrexate-naive patients, it's got a proven advantage, it's got a strong monotherapy profile, it works faster, it's not immunogenic, and it's got the mechanistic
21:01
breadth.
21:03
It inhibits so many different things, whereas the biologics are uni-dimensional in their targeting, which works or doesn't work — and maybe that's why the JAKs might be better.
21:14
But there is concern, because of the guidelines and risk-benefit calculations by experts giving expert opinion — not data-driven opinions — that methotrexate is still favored as the first-line strategy.
21:30
ORAL Surveillance and FDA warnings are telling you maybe you shouldn't use it.
21:37
If you've got a lawyer next door who's your brother-in-law and you practice medico-legal first, then yeah, maybe you won't be doing that.
21:49
But again, what would you use in someone close to you who really needed aggressive therapy, who really needed to get better right quick, as they say here in Texas?
22:01
I believe that JAK inhibitors will dominate our clinical arena, especially in RA, for the next 25 years. What am I waiting for?
22:10
I'll end with two quotes. "It's unbelievable how much you don't know about the game you've been playing your whole life."
22:17
That's a quote from the great Mickey Mantle.
22:22
Another quote from another famous ball player — Sir William Osler — said, "Medicine is a science of uncertainty and the art of probability."
22:30
I think that's what we're talking about here. Tune in for more next week.
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.